Drug Trial Radar · NCT03608020
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
Last checked: Nov 19, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
35
Actual
Start
Oct 4, 2018
Primary completion
Dec 31, 2023
Study completion Apr 15, 2024
Sponsor
- Lead sponsor
- BioMimetix JV, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Duke Cancer Institute; National Cancer Institute (NCI)
- First posted
- Jul 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2 clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain metastases (MBM) undergoing whole brain radiation therapy (WBRT). Preliminary studies have demonstrated that BMX-001 provides protection of normal tissues from radiation-induced injury and augments tumor growth inhibition.
Conditions
- Multiple Brain Metastases
Interventions
BMX-001Drug
Manganese butoxyethyl pyridyl porphyrin
Whole Brain Radiation TherapyRadiation
Whole Brain Radiation Therapy per standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess safety and tolerability of WBRT + BMX-001 through proportion of patients who experience grade 4 or 5 study drug related adverse events.Time frame: 1 year
- Compare neurocognition in WBRT + BMX-001 vs. WBRT alone using cumulative score of HVLT-R, TMT A&B and COWA over time.Time frame: 1 Year
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Kentucky
Lexington, Kentucky
Henry Ford Hospital
Detroit, Michigan
Duke Cancer Institute
Durham, North Carolina
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.